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The M3 protein (M3) encoded by murine gammaherpesvirus 68 (MHV-68) is a unique viral
immunomodulator with a high-affinity for a broad spectrum of chemokines, keymediators
responsible for the migration of immune cells to sites of inflammation. M3 is currently
being studied as a very attractive and desirable tool for blocking the chemokine signaling
involved in some inflammatory diseases and cancers. In this study, we elucidated the
role of M3 residues E70 and T272 in binding to chemokines by examining the effects
of the E70A and T272G mutations on the ability of recombinant M3, prepared in
Escherichia coli cells, to bind the human chemokines CCL5 and CXCL8. We found
that the E70A mutation enhanced binding of M3 to CCL5 two-fold but had little effect
on its binding to CXCL8. In contrast, the T272G mutation was found to be important
for the thermal stability of M3 and significantly decreased M3’s binding to both CCL5
(by about 4×) and CXCL8 (by about 5×). We also constructed in silico models of the
wild-type M3–CCL5 and M3–CCL8 complexes and found substantial differences in their
physical and chemical properties. M3 models with single mutation E70A and T272G
suggested the role of E70 and T272 in binding M3 protein to chemokines. In sum, we
have confirmed that site-directed mutagenesis could be an effective tool for modulating
the blockade of particular chemokines by M3, as desired in therapeutic treatments for
severe inflammatory illnesses arising from chemokine network dysregulation.
Keywords: MHV-68, M3 protein, site-directed mutagenesis, chemokine binding, CCL5, CXCL8, complex modeling,
molecular recognition
INTRODUCTION
Chemokines are low molecular weight, chemoattractant cytokines (classified into four
subfamilies—CC, CXC, CX3C, and C according to the position of their N-terminal cysteine
residues) that modulate the migration of immune cells from blood vessels to sites of infection and
inflammation, an important phenomenon in host defense (Zlotnik and Yoshie, 2000). Chemokines
establish gradients through specific interactions with glycosaminoglycans (GAGs) expressed on
endothelial cell surfaces (Proudfoot et al., 2003) and direct target cell migration and activation by
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binding to G-protein-coupled chemokine receptors (GPCRs)
(Sallusto and Baggiolini, 2008; Burg et al., 2015). Thus,
chemokines play an important role in host defense against
invading pathogens. It has been established that chemokines
are associated with disease progression and are also implicated
in hematopoiesis, angiogenesis, and development. Besides
their well-documented role in many inflammatory diseases,
chemokines also have a role in cancer development
(Chow and Luster, 2014).
Given the central role that chemokines play in antiviral
defense, it is not surprising that many viruses have evolved
strategies to alter host chemokine function to their benefit
(Alcami and Koszionowski, 2000). Viruses have acquired
and optimized molecules that interact with the host
chemokine network. They express a repertoire of proteins
which interfere with the host immune response in order to
avoid being eliminated from the organism. Virus-encoded
immunomodulatory proteins target or bind to chemokines
and their receptors and thus specifically modulate chemokine
gradient formation and ligand-receptor recognition; they even
have the potential to completely block chemokine-mediated
responses to viral infection. They are used to promote cell entry,
facilitate dissemination of infected cells, and interfere with
extracellular chemokines (Alcami, 2003).
Virus-encoded immunomodulatory proteins have been
identified from many virus families, with the majority being
derived from DNA viruses, from which poxviruses and
herpesviruses have evolved to encode the largest number of
immunomodulators, called viral chemokine binding proteins
(vCKBPs) (Alcami and Lira, 2010). So far, five vCKBP subfamilies
have been described, which differ in specificity as well as in
chemokine interaction mechanisms. However, only a few of
them have been tested for their therapeutic potential in vivo
even though neutralizing chemokine signaling is a very attractive
therapeutic strategy for many diseases. The most recently
discovered class of herpesvirus immunomodulators include
the only two known chemokine-binding proteins encoded by
gammaherpesviruses. They are the M3 protein from murine
gammaherpesvirus 68 (MHV-68) and the R17 protein from
the rodent herpesvirus Peru, which both show no significant
homology to mammalian proteins (Heidarieh et al., 2015;
González-Motoz et al., 2016).
MHV-68, from the genus Rhadinovirus (Van Regenmortel
et al., 2000), closely related to human gammaherpesviruses
(Kúdelová and Rajcˇáni, 2010), was isolated from murid rodents
ofMyodes spp. captured in the former Czechoslovakia (Blaškovicˇ
Abbreviations: BHK-21, baby hamster kidney cells; CCL2/MCP-1, chemokine
ligand 2/monocyte chemoattractant protein 1; CCL5/RANTES, chemokine
ligand 5/regulated upon activation, normal T cell expressed and secreted;
CD spectroscopy, circular dichroism spectroscopy; CXCL8/IL-8, chemokine
ligand 8/interleukin-8; ELISA, enzyme-linked immunosorbent assay; GAG,
glycosaminoglycans; IMAC, immobilized metal affinity chromatography; IPTG,
isopropyl β-D-1-thiogalactopyranoside; M3, M3 protein; MHV-68, murine
gammaherpesvirus 68; MRW, mean residue weight; NTD or CTD, N-terminal
or C-terminal domain of M3 protein; vCKBP, viral chemokine-binding protein;
wtM3, wild-type M3 protein.
et al., 1980). In addition to MHV-68, the closely related MHV-
72, and MHV-4556 strains have also been thoroughly studied
with respect to their pathogenicity and molecular properties
(Rajcˇáni and Kúdelová, 2007). Recently, MHV-68 pathogenesis
was also shown in ticks, thereby making MHV-68 an arthropod-
borne virus (arbovirus) (Hajnická et al., 2017; Kúdelová and
Štibrániová, 2019). Most recent studies, however, have focused
on the immunomodulatory M3 (44 kDa) encoded by MHV-68,
which has an exceptional ability among viral immunomodulators
to bind a wide range of chemokines (van Berkel et al., 2000).
The M3 protein was found to be the first example of a
soluble inhibitor encoded by a herpesvirus (secreted from cells
in large amounts during MHV-68 infection) and is currently
the only such protein known to bind and inactivate chemokines
from all four chemokine subfamilies. It specifically interacts
with the N-terminal chemokine binding domain of the GPCR,
thereby blocking receptor recognition and inhibiting chemokine-
mediated leukocyte migration (Alexander et al., 2002; Sarawar
et al., 2002; Webb et al., 2003). So far, M3 was shown in vivo
to reducemononuclear cellular responses afterMHV-68-induced
meningitis in mice (van Berkel et al., 2002). Along with studies
exploring its molecular properties, a variety of animal models
have been developed to test the biological and pharmaceutical
properties of M3 (Lira et al., 2009), but they mainly relate to its
potential use in gene therapy. Jensen et al. (2003) demonstrated
that M3 expression in the pancreas of mice inhibits recruitment
of lymphocytes induced by transgenic expression of CCL21 in
this organ. Induction of M3 gene expression resulted in a 67%
reduction in intimal area, suggesting that M3 may be effective
in attenuating the intimal hyperplasia associated with arterial
stenosis (Pyo et al., 2004). M3 expression overcame the cellular
inflammatory responses in rat hepatocellular carcinoma lesions
induced by a recombinant oncolytic vesicular stomatitis virus,
prolonged the therapeutic effect of this virus, and improved
animal survival (Wu et al., 2008). Recombinant M3 also inhibited
angiogenesis and neovascularization (Andrés et al., 2009). Studies
on double transgenic mice expressing both M3 and different
chemokines in pancreatic islets explored the role of chemokines
and the effects of M3 on the development of diabetes mellitus type
I. They showed that M3 can effectively inhibit mixed populations
of chemokines preventing diabetes development in mice (Martin
et al., 2007). Millward et al. (2010), using an experimental
autoimmune encephalomyelitis animal model, showed that M3
expressed directly in the CNS significantly reduced the number
of immune cells infiltrating the CNS as well as the clinical severity
of the disease, suggesting M3 could be a novel therapeutic for
neuroinflammatory diseases. M3 has therefore been suggested as
a novel tool for blocking chemokine signaling, which is highly
desirable for anti-inflammatory therapies.
The earliest studies on the biological properties of the
406-residue MHV-68 M3 showed that it bound to a broad
spectrum of chemokines, with the lowest binding affinities to
members of the CXC subfamily (van Berkel et al., 2000). Our
previous studies on the MHV-68 M3 and MHV-72 M3, either
secreted into the media of infected BHK-21 cells or prepared
recombinantly in E. coli cells, showed that M3 binds very
strongly to only one of the human chemokines tested, CCL5
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(other tested ones included CCL2, CCL3, CCL5, CCL11, and
CXCL8) (Belvonciková et al., 2008; Matúšková et al., 2015).
Studying the crystal structure of the M3–CCL2 complex (also
known as monocyte chemoattractant protein 1 or MCP-1)
helped to describe how this viral protein might be able to bind
chemokines despite having no amino-acid sequence homology
to host chemokine receptors (Alexander et al., 2002). Due to the
complex structure of M3 and the broad spectrum of chemokines
it can potentially bind, the exact functions of its individual
domains remain poorly understood.
Early studies on MHV-72 revealed a single residue
substitution, D307G, in M3, which lies close to the C-terminal
M3–CCL2 binding region (Belvonciková et al., 2008). Unlike
MHV-68, MHV-72 elicits a weaker immune response but
shows stronger oncogenicity in experimentally infected mice.
Additional studies on MHV-72 M3 purified from the media
of infected BHK-21 cells showed that its binding to CCL5
and CXCL8 was about 10 and five times lower, respectively,
than the binding of MHV-68 M3. Recent biochemical studies
on recombinant M3’s prepared in E. coli cells showed that
the D307G substitution in MHV-72 M3 was responsible for
a large decrease in its CCL3 binding relative to MHV-68 M3
(Matúšková et al., 2015). Our more recent study of recombinant
MHV-68 M3 prepared from insect cells revealed that the
deletion of the M3 signal peptide allows stronger binding to
CCL5, but not to CXCL8 (Šebová et al., 2017). Taken together,
our results prompted this work to investigate the impact of
particular amino-acid substitutions which are not part of the
M3–chemokine interface on the ability of MHV-68 M3 to bind
to individual chemokines using site-directed mutagenesis.
The aim of this study was to better clarify the structural basis
for the specific activities of M3 by identifying those residues
which could alter its binding to individual chemokines, and those
mutations which either enhance or suppress these activities. We
selected and introduced two unique mutations into MHV-68
M3, one located in its N-terminal domain (NTD)—E70A—and
another in its C-terminal domain (CTD)—T272G. To determine
the effect of these mutations on chemokine binding, we prepared
two mutant recombinant M3’s incorporating each mutation
individually and investigated their effects on the binding of the
CCL5 and CXCL8 chemokines. We examined the effect of the
most effective mutation, T272G, on the thermal stability and
folding of M3 by CD spectroscopy. To understand the effect of
both mutations on chemokine binding, we created and analyzed
in silico models of the M3 E70A and T272G mutants. To gain
better insight into M3 chemokine recognition, we created new
in silico models of complexes wtM3 with CCL5 and CXCL8 and
compared them to the known X-ray crystal structures of the
wtM3–CCL2 and wtM3–XCL1 complexes.
MATERIALS AND METHODS
Virus and Cells
MHV-68 originally isolated from Myodes glareolus was kindly
provided by Prof. Mistríková (Comenius University, Slovakia).
MHV-68 was subsequently twice plaque-purified to obtain
clone f2.6 and then propagated using BHK-21 fibroblasts
(ATCC number: CCL-10) as described previously (Raslova
et al., 2001). Cell cultures were maintained in Dulbecco’s
Minimum Essential Medium (Gibco) supplemented with
10% (v/v) fetal bovine serum (FBS), 2 mmol/l glutamine
(Invitrogen) and penicillin–streptomycin–amphothericin
(Cambrex) at 37◦C. E. coli Rosetta-gami 2 (DE3) competent cells
(Novagen) were used to express recombinant M3’s following the
manufacturer’s instructions.
Cloning and Site-Directed Mutagenesis
Pure MHV-68 virion DNA, purified as previously described
(Raslova et al., 2001) was used as a template to amplify a fragment
encoding the full-length MHV-68 M3 protein sequence carrying
a His-tag anchor at its C-terminal end as described in Pancˇík
et al. (2013). This DNA fragment was cloned into a pET26b(+)
expression vector (Novagen) to create the recombinant plasmid
P26-M3his/68. Next, two expression vectors with different
single mutations to the M3 gene (P26-M3his/68E70A and P26-
M3his/68T272G) were prepared using primers incorporating
mutations (Table S1), together with the Stratagene QuickChange
site-directedmutagenesis kit (Agilent Technologies) according to
the manufacturer’s instructions. Both strands of all expression
plasmids used here were sequenced to confirm the cloned
fragments had the correct sequences (BITCET, Slovakia).
Expression, Purification and
Immunoblotting of wtM3, M3-E70A, and
M3-T272G Proteins
To produce each recombinant M3, we followed the optimized
protocol previously described (Matúšková et al., 2015) with slight
differences. Briefly, the expression of recombinant M3 from E.
coli competent cells was induced by IPTG at a final concentration
of 0.5 mmol/l and then carried out for 3 h at 37◦C. The cells
were sonicated in lysis buffer containing 50 mmol/l Tris-HCl pH
8, 500 mmol/l NaCl, 10% (w/v) glycerol, 10 mmol/l imidazole,
and 0.2% (w/v) sulfobetaine-14 (Sigma-Aldrich). Soluble His-
tagged recombinant protein was then purified from the lysate
supernatant using IMAC with HIS-Select Cobalt Affinity Gel
(Sigma Aldrich). To elute M3, buffer A containing 50 mmol/l
Tris-HCl pH 8, 500mmol/l NaCl, 10% (w/v) glycerol, 250mmol/l
imidazole, and 0.2% (w/v) sulfobetaine-14 was used. The amount
of M3 in the elution fractions was quantified using a NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific). SDS-PAGE
and western blotting were performed to confirm the size, purity
and specificity of M3 recovered using the anti-M3 antibody 1/27
(Šebová et al., 2017).
ELISA
Recombinant proteins wtM3, M3-E70A, and M3-T272G were
tested for their ability to inhibit commercial recombinant
CCL5 and CXCL8 using the Human CCL5/RANTES and
Human CXCL8/IL-8 DuoSet ELISA kits (R&D Systems). Each
M3–chemokine interaction was tested in three independent
experiments. In ELISA assays, 50 pg of a given recombinant
chemokine was mixed with six different amount of tested
recombinant M3 (2, 10, 20, 100, 200, and 400 ng) to achieve
final concentrations: 4.5 × 10−11, 2.25 × 10−10, 4.5 × 10−10,
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2.25 × 10−9, 4.5 × 10−9, and 9 × 10−9 mol/l in a volume
of 110 µl. Each mixture was incubated at 21◦C for 1.5 h with
gentle shaking and then applied to ELISA plates (Greiner Bio-
one) following the manufacturer’s instructions, but using ortho-
phenylenediamine as the substrate. Each sample (examined in
triplicate) was measured using an ELISA reader (EL × 808,
BioTek) with buffer A serving as a negative control. A reduction
in the sample’s OD492 relative to that of 50 pg chemokine without
M3 was determined as the rate of chemokine inhibition (%)
by M3 present in assay in given concentration. To compare
the strength of binding of wtM3, M3-E70A, and M3-T272G to
chemokine, data were expressed as IC25 or IC50 interpreting
the quantity of the given protein needed to remove 25 or 50%
of a given chemokine from solution, in other words protein
concentration that inhibit 25 or 50% of chemokine used in the
assay. Statistical significance was determined using a two-tailed
unpaired Student t-test ∗∗∗, p < 0.001 (GraphPad Software),
using as null that there was no difference in binding relative
to wtM3.
Circular Dichroism Spectroscopy
CD spectra were recorded on an Aviv Model 215 spectrometer
(Aviv Biomedical Inc., Lakewood) equipped with a thermostatted
cell holder. Proteins were dialyzed into a buffer containing 30
mmol/l Tris-SO4, pH 8.0, 250 mmol/l NaF, 0.1% sulfobetaine
14 (w/v), and 3% glycerol (v/v) at 4◦C. Far-UV spectra (260–
185 nm) were collected in a 0.2 (wtM3) or 0.5mm (M3–
T272G) quartz cuvette at 4, 16, 25, 35, 45, 50, 60, 70, and
80◦C (80◦C for wtM3 only) at protein concentrations of 0.35
(wtM3) or 0.17 mg/ml (M3–T272G), with 4 s accumulation times
per point at 0.2 nm intervals using a 1 nm bandwidth. After
heating, a further 4◦C spectrum was recorded after cooling at
a rate of 4◦C/min. Buffer baselines were subtracted, data were
smoothed, and normalized to mean residue weight ellipticities
[θ]MRW. Protein concentration was determined from absorption
at 280 nm assuming an extinction coefficient of ε280 = 50,600
M−1cm−1. Secondary structure content was estimated using
the CDsstr algorithm (Johnson, 1999) as implemented in the
Dichroweb server (Whitmore and Wallace, 2004) with the
SMP180 reference data set (Lees et al., 2006).
In silico Modeling of the M3-E70A and
M3-T272G MHV-68 Mutant Proteins
Models of theM3-E70A andM3-T272G were created using Swiss
Model (Waterhouse et al., 2018). To do the modeling, three
template structures were selected (PDB IDs: 1MKF, 1ML0, and
2NYZ). Models were built based on a target-template alignment
using ProMod3. Coordinates which were conserved between the
target and the template were copied from the template to the
model. Insertions and deletions were remodeled using a fragment
library. The side-chains were then rebuilt. Finally, the geometry
of the resulting model was regularized using the GROMOS96
force field (Van Gunsteren et al., 1996). The global and per-
residue model quality was assessed using the QMEAN scoring
function (Benkert et al., 2011).
In silico Modeling of Complexes of CCL5
and CXCL8 Chemokines With wtM3
MHV-68 Protein and Its E70A and T272G
Mutant Forms
Models of the complexes between wtM3 and the CCL5
and CXCL8 chemokines were prepared based on previously
determined wtM3–chemokine complex crystal structures. The
wtM3–CCL5 complex model was based on the wtM3–CCL2
complex (PDB ID 2NZ1; Alexander-Brett and Fremont, 2007)
using a recent structure of CCL5 alone for the chemokine
(5COY; Liang et al., 2016). The wtM3–CXCL8 complex model
was based on the wtM3–XCL1 complex (2NYZ; Alexander-
Brett and Fremont, 2007) using a recent structure of CXCL8
for the chemokine (4XDX, unpublished). To construct each
model, the model of a given M3 form or chemokine were
superimposed onto the corresponding template protein structure
by Cα atom overlap using LSQKAB (Kabsch, 1976), part of
the CCP4 suite (Winn et al., 2011). For the chemokines,
the overlap used 60 Cα atoms for CCL5–CCL2 and 55 for
CXCL8–XCL1. These atoms came mainly from the core and
C-terminal α-helix of each chemokine structure; all Cα atoms
with rmsds over 2.0 Å were excluded from the comparison.
Possible clashes were removed by energy minimization against
the AMBER99SB-ILDN force field (Lindorff-Larsen et al., 2010)
using steepest descent and conjugate gradient minimization as
implemented in GROMACS 5.1.3 (Abraham et al., 2015). All
hydrogen atoms were removed before the following analyses.
The model and crystal structure complexes were analyzed
using the COCOMAPS (Vangone et al., 2011) and PISA
(Krissinel and Henrick, 2007) servers; interacting residues
were also identified using the CCP4 program NCONT with a
maximum contact distance of 4 Å. The electrostatic surfaces
were calculated using APBS (Jurrus et al., 2018) and visualized
using PyMOL 1.8.6 and 2.0 (Schrödinger) using the APBS Tools
2.1 plugin.
RESULTS
Selection of Amino Acid Residues for
Mutagenesis
Based on current knowledge of how the M3 structure allows it
to bind all chemokine subfamilies, and on the known M3–CCL2
complex crystal structure, we selected two amino-acid residues,
E70 and T272, expected to be near the M3 chemokine binding
site. E70 is in the M3 NTD (1–234), and T272 is in the CTD
(235–406) (Figures 1A,B); both are close to sequences known
to be involved in binding chemokine CCL2 (E104–I110, A261,
and Y290–A299) (Diaz et al., 2009). According to the known
complexes of M3 with CCL2 (PDB ID 2NZ1) and XCL1 (PDB
ID 2NYZ) (Alexander-Brett and Fremont, 2007), neither of the
selected residues are directly part of the chemokine binding site.
In the M3 MHV-68 tertiary structure (PDB ID 1MKF), E70 is
a surface-exposed residue and is part of an α-helix containing
residues 69–82 (Figure 1B). It is surrounded by the negatively
charged residues E55 and E65. E65 is part of a 7-residue loop
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FIGURE 1 | Structural analyses of MHV-68 wtM3 protein. (A) The amino-acid sequence of wtM3 including the N-terminal signal sequence, and the N-terminal (NTD)
and C-terminal domains (CTD). Residues here and throughout the text are numbered according to the full-length sequence, beginning with the N-terminal signal
sequence. Residues thought to be involved in CCL2 binding are in turquoise (Diaz et al., 2009); those chosen for mutation, E70 and T272, are colored magenta.
Secondary structure elements, α-helices and β-strands, are marked as red rectangles and yellow arrows, respectively. (B) The tertiary structure of the 406-residue
MHV-68 M3 (PDB ID 1MKF). Residues E70 and T272, selected for mutation to A and G, respectively, are shown as balls and sticks. (C) The conformation of E70 and
the surrounding residues E55, E65, H59, and V68 (shown as sticks) in the structure of wtM3. The hydrogen bond between the E70N and V68 O is shown as a dashed
line. Residues 331–335 from the neighboring M3 molecule in the M3 dimer are shown in olive green. (D) The hydrogen bond network formed by T272 Oγ1 with Q396
Oε1, A281N, and Q279 O (all shown as sticks) in the wtM3 structure. The hydrogen bond between Q396 Oε1and the phenolic OH group of Y398 is also shown.
(61–68) and its side-chain makes a face-to-edge interaction with
the imidazole ring of H59 from a neighboring α-helix. The
main-chain N of E70 hydrogen bonds to the main-chain O of
V68 (Figure 1C). The crystal structure shows that MHV-68 M3
exists as a dimer, and the loop containing residues 61–68 makes
contacts with the second M3 molecule in the dimer by hydrogen
bonding to the N331 and R334 side-chains. E70 therefore helps
in part to stabilize the conformation of both its own and a
neighboring α-helix, and also contributes to the conformation
of the 61–68 loop contacting the second M3 molecule in the M3
dimeric structure.
Threonine 272 is part of an 11-residue loop (270–280); its
Oγ1 side-chain atom is buried within the M3 structure and
forms a hydrogen bond network with Q396 Oε1, Q279 O and
A281N (Figure 1D). These interactions help to stabilize not
only the conformation of the 11-residue loop, but also, in part,
the position of the following two β-strands (residues 281–284
and 396–401).
Before carrying out the mutations, we checked the likely
effect of exchanging E for A at residue 70 and T for G at
residue 272 on the physico-chemical properties and the surface
exposure of the resulting M3 mutant proteins. Using ProtParam
(Gasteiger et al., 2005) we found that these mutations should
have minimal effect on their pI and instability indices, and
that their solubility indices are expected to increase by 8
and 10% for M3-E70A and M3-T272G, respectively (Table S2).
Based on the Kyte-Doolittle and Hopp-Woods methods and on
surface exposure analysis (Kyte and Doolittle, 1982), a decrease
in the hydrophilicity/hydrophobicity profile and the surface
exposure area close to the mutation site was calculated for
the E70A mutation (Figure S1): this was expected as the E70
side-chain is surface exposed and its replacement by alanine
reduces the negative charge on the surface of the protein. Only
a minimal decrease in exposed surface area and no change
in hydrophobicity/hydrophilicity was calculated for M3-T272G
protein (Figure S1).
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Expression and Purification of
Recombinant MHV-68 M3 Proteins
We transformed E. coli Rosetta-gami 2 (DE3) cells with
recombinant bacterial expression vectors carrying either wild-
type or mutant M3 genes; each of them expressed relatively
efficiently in these cells (Figure S2). Analyses of the cell lysate
supernatant by SDS-PAGE confirmed that each recombinant M3
was of the expected size,≈ 44 kDa (Figure 2), with yields of 0.5–2
mg/l culture media. All recombinant proteins, wtM3, M3-E70A,
and M3-T272G (Figure 2A), were detected by Western blotting
using the primary anti-M3 antibody 1/27 (Figure 2B). All three
recombinant M3’s were obtained in sufficient quantity for the
following studies.
Binding of Recombinant M3 Proteins to
Chemokines
ELISA assays demonstrated that wtM3 and both mutant
forms were able to bind both CCL5 and CXCL8, but with
altered affinities. Testing the binding of recombinant M3’s with
concentration ranges on the order of 10−10 to 10−7 mol/l
to both chemokines we found that wtM3 and M3-E70A, but
not M3-T272G, were able to inhibit more than 50% of CCL5
(Figure 3A). The IC50 value of M3-E70A and wtM3 was 8.7
nmol/l and 16.2 nmol/l, respectively, indicating that affinity of
M3-E70A to CCL5 was roughly twice the affinity of wtM3. As
FIGURE 2 | Analyses of purified wtM3 and mutant M3-E70A and M3-T272G
proteins. (A) SDS-PAGE on a 12.5% gel; (B) western blotting.
shown in Figure 3B, no of M3 was able to inhibit more than 50%
of CXCL8; however, the affinities of wtM3 and the M3-E70A and
M3-T272G mutants for both CCL5 and CXCL8 were assessed
using IC25 values (derived from plots data on Figure 3) allowing
the strength of all tested M3-chemokine interactions to be
compared. As Figure 4 shows, M3-E70A was able to bind CCL5
with roughly twice the affinity of wtM3 (IC25 of 3.5 nmol/l vs. 7.1
nmol/l for wtM3) while CXCL8 showed only a modest reduction
of 1.2× (IC25 of 11.5 nmol/l vs. 8.7 nmol/l for wtM3). The T272G
mutation, however, significantly reduced the affinity of M3 for
both chemokines: M3-T272G bound CCL5 with an IC25 of 30.2
nmol/l and CXCL8 with 42.5 nmol/l, increases of around 4× and
5×, respectively, over wtM3 (Figure 4). These results suggest that
T272 is important for binding to both chemokines.
In silico Models of the wtM3 in Complex
With CCL5 and CXCL8
To better understand the ability of M3 to bind the CCL5 and
CXCL8 chemokines, and the cause of the diminishing of this
FIGURE 4 | Comparison of the strength of binding of wtM3 and mutant
M3-E70A and M3-T272G proteins to (A) CCL5 and (B) CXCL8. IC25
expresses the protein concentration needed to bind 25% of the chemokines
used in the assay. The *** above the results of each mutant indicates that the
difference from wtM3 is statistically significant at the p < 0.001 level. The
results shown are an average of three independent experiments.
FIGURE 3 | Binding of wtM3 and mutant M3-E70A and M3-T272G proteins to CCL5 (A) and CXCL8 (B) as determined by ELISA. Each chemokine assay was done
in triplicate.
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TABLE 1 | Superposition of the Cα traces of the given chemokines on CCL5 and
CXCL8.
CXCL8
(4XDX)
CCL2
(2NZI)
XCL1
(2NYZ)
CCL5
(5COY)
Rmsd: 1.6 Å
Maximum
Displacement: 4.4 Å
No. of compared
Cα atoms: 41
Rmsd: 0.7 Å
Maximum
Displacement: 2.1 Å
No. of compared
Cα atoms: 60
Rmsd: 0.9 Å
Maximum
Displacement: 2.6 Å
No. of compared
Cα atoms: 58
CXCL8
(4XDX)
– Rmsd: 1.6 Å
Maximum
Displacement: 3.4 Å
No. of compared
Cα atoms: 56
Rmsd: 1.4 Å
Maximum
Displacement: 3.9 Å
No. of compared
Cα atoms: 55
L2, XCL1, and CXCL8 Cα traces were overlapped using LSQKAB (Kabsch, 1976).
binding by the E70A and T272G mutations, we constructed
models of complexes between wtM3 and the CCL5 and
CXCL8 chemokines.
To date, the only crystal structures of MHV-68 M3–
chemokine complexes are with the CCL2 and XCL1 chemokines
(Alexander et al., 2002; Alexander-Brett and Fremont, 2007).
To find the best template structure for creating our model
complexes, we compared the Cα traces of CCL5 and CXCL8
to those of CCL2 and XCL1 (Table 1; Figure S3). All four
chemokines had similar overall structural folds, especially in the
area of the three-stranded antiparallel β-sheet and the C-terminal
α-helix; the largest differences were found in the N-terminal
loop and the loop containing residues 30–36 (Figure S3; CCL5
numbering). It is also noteworthy that CXCL8 had the longest
C-terminal α-helix. CCL5 and CCL2 had the highest structural
similarity, with an rmsd of 0.7 Å. CXCL8 was most similar to
XCL1, with an rmsd of 1.4 Å, which was slightly better than its
similarity to CCL2 and CCL5, both 1.6 Å. To model the wtM3–
CCL5 complex, therefore, we used the wtM3–CCL2 complex as a
template and to model the wtM3–CXCL8 complex, we used the
wtM3–XCL1 complex.
Comparing the modeled wtM3–CCL5 and wtM3–CXCL8
complexes with the experimental wtM3–CCL2 and wtM3–
XCL1 complexes revealed differences in the size, amino-acid
composition, charge and number of contact residues and salt
bridges of the interface areas (Table 2). The wtM3–CXCL8
complex had the largest interface area (1295 Å2 corresponding
to 4 and 24% of the wtM3 and CXCL8 protein surfaces,
respectively), with the largest number of contact residues
(25 and 22 for wtM3 and CXCL8, respectively) and the
greatest number of hydrogen bonds and charged interactions.
Charged interactions are likely to play a crucial role in
the formation of this complex, since five salt bridges were
identified. Uniquely, of the four analyzed complexes, this was
the only one to have charged residues from both the NTD
and the CTD of M3 take part (Table 2; Figure 5C); the
remaining three complexes had salt bridges to only residues from
the NTD.
The wtM3–CCL5 complex had the second largest interface
area (1171 Å2 corresponding to 3.6 and 24.4% of the wtM3
TABLE 2 | Analysis of the M3–chemokine interface areas.
Complex wtM3–
CCL5
wtM3–
CCL2*
wtM3–
CXCL8
wtM3–
XCL1#
† Interface area (Å2)
%wtM3/%chemokine
1,171
(3.6/24.4)
1,042
(3.2/22.5)
1,295.4
(4.1/24)
1,078
(3.4/21.9)
†Polar interface area
Å2 (%)
770.6
(65.8)
653.5
(62.7)
808.1
(62.4)
678.45
(62.9)
†Non-polar interface
area Å2 (%)
400.5
(34.2)
388.6
(37.3)
487.2
(37.6)
400 (37.1)
†Contact residues 22/24 25/19 25/22 21/19
†Hydrophilic
interactions
15 20 19 13
†Hydrophobic
interactions
12 7 9 10
$Hydrogen bonds
within 3.5 Å
14 16 17 10
$Charge interactions
within 3.5 Å
3
E105/K45
E153/R17
D166/K55
2
E105/K49
E153/R18
6
E105/R47
E145/K20
E153/K15
E194/H18
K252/D45
D301/R6
1
E104/R23
†Performed by the COCOMAPS server (Vangone et al., 2011).
$Performed by the PISA server (Krissinel and Henrick, 2007).
*,#2NZ1 and 2NYZ PDB structures (side chains A,B, and D) were used.
and CCL5 protein surfaces, respectively). The amino-acid
composition of this complex interface is rather different
from that of wtM3–CXCL8: it contains more hydrophobic
residues and a smaller number of polar and charged residues
(Figures 5A,E). This interface has the highest number of
hydrophobic interactions and only three salt bridges (Table 2).
The interfaces of the wtM3–CCL2 and wtM3–XCL1
complexes have similar areas (1042 and 1078 Å2, respectively;
Table 2), and are both smaller than either the wtM3–CCL5
or wtM3–CXCL8 interfaces. Of the four complexes, the
wtM3–CCL2 interface has the largest number of hydrophilic
interactions, but only two salt bridges (Table 2; Figure 5C), while
the wtM3–XCL1 interface has the lowest number of hydrophilic
interactions and only one salt bridge (Table 2; Figure 5D).
Common to all four complexes are the charged and polar
interactions between Q108, Y149, Y151, T196, S293, and S295 of
wtM3 with their unconserved counterparts in each chemokine
(Figures 5A–D). There is also a common conserved charged
interaction between E105 (for the wtM3–CCL2, wtM3–CCL5,
and wtM3–CCXL8 complexes) or E104 (wtM3–XCL1 complex)
with a lysine or arginine from the bound chemokine. It is worth
noting that most of the negatively charged and polar residues
contributed by M3 come from its NTD (L106 is the only non-
polar NTD residue) while the CTD contributes some polar
residues but also hydrophobic ones. The CTD especially prefers
proline, serine, tyrosine, valine and leucine residues. P296 is
a good example: in all four wtM3–chemokine complexes, it is
buried in a hydrophobic cavity formed by the surface of the
interacting chemokine (Figures 5A–D).
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FIGURE 5 | Interfaces of modeled wtM3 complexes with CCL5 and CXCL8 and crystal structures of wtM3 with CCL2 and XCL1. (A–D) show those residues of the
NTD (salmon) and CTD (gray) of wtM3 within 4 Å of residues from the CCL5 (A), CCL2 (B), CXCL8 (C), and XCL1 (D) chemokines. Residues which interact with all
(Continued)
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FIGURE 5 | four chemokines are labeled in magenta. The electrostatic surface of each chemokine is shown (range ±5 kT/e). These surfaces were prepared using
APBS (Zhou et al., 2000) and displayed using PyMOL. (E) Structure-based sequence alignment of CCL5, CCL2, CXCL8, and XCL1. The secondary structure
elements of each chemokine are indicated above its sequence (α-helices are red, 310 helices are pink and β-sheets are yellow). Residues which are identical (*) in all
four structures are indicated. Chemokine residues which interact with the M3 NTD and CTD colored blue and red, respectively. Residues which form salt bridges at
the M3-chemokine interface are printed larger. Cysteines forming disulphide bonds are undercoated with the same color.
FIGURE 6 | Surface electrostatic charge distribution of wtM3 and modeled M3-E70A and M3-T272G mutants. (A,C) Electrostatic charge distribution calculated for
the surface of wtM3. (B,D) Surface electrostatic charge distribution for the E70A-M3 and T272G-M3 mutants. Areas with a change in charge distribution between the
given M3 mutant and the wild-type protein are circled. The interacting chemokine in one of the two chemokine binding sites is shown as a green ribbon. The
electrostatic surfaces of all M3’s are shown (range ±5 kT/e). The surface was prepared using APBS (Zhou et al., 2000) and displayed using PyMOL.
It is interesting to note that, aside from one exception in the
wtM3–CXCL8 complex (Table 2), M3 always contributes acidic
residues (glutamate and aspartate) to complex formation while
the chemokines, despite their low amino-acid sequence identity,
contribute basic ones (arginine and lysine; Table 2; Figure 5).
This is very likely an important part of chemokine recognition
by MHV-68 M3 and may be, at least in part, responsible for the
“promiscuity” of MHV-68 M3 in chemokine recognition.
Surface Analysis of the E70A and T272G
Mutant Structures
Model structures of the E70A and T272GM3mutants are almost
identical to the structure of wtM3. The main differences are in
the amount of exposed surface area and surface charge. This is
particularly noticeable in the E70A mutant, where the exposed
surface area decreases from 71 Å2 to 33.6 Å2 and a negative
charge in the mutation site and its surrounding environment
is eliminated (Figures 6A,B). Surprisingly, the T272G mutation
slightly increases the accessible surface area from 5.5 to 8.8 Å2
in the mutation site, resulting in a deeper cavity with a higher
negative charge (Figures 6C,D). The change in surface charge is
due to the exposure of the polar side-chains of Y398 and Q396,
which are in contact with T272 in the wtM3 (Figure 1D).
CD Spectroscopy of wtM3 MHV-68 Protein
and Its T272G Mutant Form
The wtM3 and mutant M3-T272G recombinant proteins were
analyzed by CD spectroscopy. Spectra recorded at 4◦C showed
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FIGURE 7 | CD spectra of the wtM3 and M3-T272 mutant proteins. Far-UV CD spectra were recorded at increasing temperatures from 4 to 80◦C for wtM3 (A) or
from 4 to 70◦C for the M3-T272 (B) mutant followed by cooling back to 4◦C. Spectra shown are for 4◦C before (black line) and after (blue) heating, and at maximum
temperature (red). Insets show the ellipticities at 220 nm as a function of temperature; the blue dots indicate [Θ ]220 after cooling.
a shoulder at 220 nm, a minimum at 208 nm and a maximum
at 192 nm (Figure 6). Deconvolution gave an α-helical content
of 15–17%, and ∼35% of β-strand conformation. These results
are in good agreement with the 13 and 38% of α-helix and β-
strand content found within the M3 crystal structures (PDB ID
1MKF; Alexander et al., 2002). This indicates that both the wtM3
and T272G adopt a native-like conformation. Spectra recorded
at increasing temperatures, up to 80◦C, exhibited only very small
changes for the wild-type protein, and cooling back to 4◦C
resulted in a>95% signal recovery (Figure 7A, inset). T272G also
produced only small spectral changes upon heating to 60◦C; a
further spectrum recorded at 70◦C, however, showed a significant
loss of signal that persisted upon cooling back to 4◦C, indicating
an irreversible structural change (Figure 7B, inset).
To better understand the role of T272 in thermal stability,
we examined its contacts with the rest of the M3 crystal
structure. T272 lies in a short, 3-residue loop (residues 271–
273) lying between the β-strand-containing residues 268–270
and a short helical turn (Figures 1B,D). Its side-chain is buried
and its Oγ1 atom is within hydrogen bonding distance of
Q396 Oε1, the A281 main-chain N and the Q279 main-chain
oxygen (Figure 1D). Furthermore, Q396 Oε1 hydrogen bonds
to the phenolic OH group of Y398. These contacts suggest
that the T272 Oγ1 atom forms a hydrogen bond network
which stabilizes the surrounding residues (Figure 1D), ultimately
making T272 involved in connecting two β-strands (those with
residues 268–270 and 396–401), which are part of the two five-
stranded β-sheets forming the core of theM3C-terminal domain.
A mutation to glycine would eliminate all these interactions,
potentially not only increasing the flexibility of the 271–273 loop,
but also the CTD core, leading ultimately to a decrease in M3
thermal stability and possible permanent denaturation, as was
observed above 60◦C by CD spectroscopy (Figure 7).
DISCUSSION
The immunomodulatory protein M3 encoded by MHV-68, a
pathogen of wild murid species rodents, attracts attention due
to its ability to bind promiscuously, but with high affinities,
to human and murine chemokines of all chemokine classes.
M3 appears to affect the host’s immune response to viral
infection in at least two different ways: it is able to bind free
chemokines, thereby blocking chemokine–receptor interactions
by competitive inhibition, and it inhibits the interaction of
chemokines with GAGs, thereby affecting the chemotactic
gradients needed for directed cell migration (Webb et al., 2004).
Due to the complex structure of M3 and the broad spectrum of
chemokines that it is able to bind, the functions of individual
M3 domains are only poorly understood, but some tentative
suggestions have been made. It is thought that the ability
of M3 to block the chemokine–GAG interaction lies in its
acidic N-terminal domain (pI = 4.30 for residues 25 to 230),
which electrostatically complements the basic chemokine clusters
involved in GAG association. On the other hand, the M3 C-
terminal domain engages with residues conserved in different
chemokine subclasses which have the same overall spatial
arrangement that are involved in receptor binding (Alexander
et al., 2002; Webb et al., 2003).
In 2008, Belvoncˇíková et al. found that MHV-72 M3 differed
from its MHV-68 counterpart in only a single-amino acid residue
located near the CCL2 chemokine-binding area. MHV-72 M3
released into the media from infected BHK-21 cells bound only
11 and 20% of the human CCL5 and CXCL8 chemokines bound
by MHV-68 M3. These results suggested that even a single
mutation could have an impact on the ability of M3 to bind
individual human chemokines. This is consistent with other
studies on chemokine binding proteins. Zhou et al. (2000) carried
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out site-directed mutagenesis to study chemokine receptor CCR5
and found that residues Y10 and K26 play critical structural roles
in ligand binding and cell signaling. Petit et al. (2008) prepared
a series of mutant CXCR6 proteins and described the effects
of individual mutations on receptor function; in particular, the
mutations D176N and D274Q made CXCR6 unable to bind to
CXCL16. Recently, White et al. (2011) carried out site-directed
mutagenesis on 35K-Fc and found that E143 is essential for
binding to chemokine CCL5. They also found that an R89A
mutation gave 35K-Fc a higher potency for blocking the CCL5
chemokine. Finally, we recently showed that the deletion of
the signal peptide (the first 24 residues) in the MHV-68 M3del
protein increased M3’s binding to CCL5, but not to CXCL8
(Šebová et al., 2017).
Creating in silico model complexes of wtM3 with CCL5
and CXCL8 and comparing them to the known X-ray crystal
structures of the wtM3–CCL2 and XCL1 complexes (Alexander-
Brett and Fremont, 2007) revealed differences in the physico-
chemical properties (size, charge, hydrophobicity, and number
of interacting residues and charged interactions) of the complex
interfaces. Investigating all four interfaces suggested that the
ability of MHV-68 M3 to bind a variety of chemokines
(Alexander et al., 2002; Webb et al., 2003) arises from a
complementary charge distribution between the receptor and
ligand, in which M3 contributes mainly negatively-charged
residues while the chemokine contributes mainly positively-
charged ones. The importance of charged interactions was
also shown previously by a kinetic analysis of wtM3 with
XCL1 (Alexander-Brett and Fremont, 2007). Our results also
showed that there is a principal difference in the interactions
between the NTD (mostly charged and polar residues) and the
CTD (mostly polar and hydrophobic residues) of M3 with the
bound chemokine.
The crystal structure of M3 bound to the CCL2 chemokine
revealed several key regions at the interface between M3
and CCL2 (Alexander et al., 2002). Based on the published
complex structure of M3 and CCL2, we constructed a series
of recombinant mutant proteins targeting residues near the
CCL2-binding area and tested their function in vitro. To test
the chemokine binding properties of these proteins, which
specifically bound the anti-M3 1/27 antibody (Šebová et al.,
2017), we chose two human chemokines: the inflammatory
chemokine CCL5 suggested to be involved in melanoma and
in tumor growth and progression (Aldinucci and Colombatti,
2014) and CXCL8, which is highly involved in wound healing and
triggering the infiltration of bothmacrophages and neutrophils in
cystic fibrosis (Raman et al., 2007) and is associated with a highly
metastatic cancer phenotype (Liu et al., 2016).
Here, based on in silicomodel complexes of wtM3 with CCL5
and CXCL8, we created two M3 mutant proteins with single
amino-acid substitutions, E70A and T272G and in E. coli cells
prepared mutant M3-E70A and M3-T272G proteins using site-
directed mutagenesis. Analyzing the ability of each mutant M3 to
inhibit both CCL5 and CXCL8 chemokines compared to wtM3
using an ELISA assay showed that neither mutation resulted in
a complete loss of M3 function; M3 mutants were still able to
bind both chemokines. However, the introduction of each given
mutation produced different effects on the affinity of M3 for
the tested chemokines. As shown in Figure 3, while the E70A
mutation doubled the affinity of M3 for CCL5 relative to wtM3
(IC50 of 8.7 vs. 16.2 nmol/l for wtM3; IC25 of 3.5 vs. 7.1 nmol/l
for wtM3), the T272G mutation reduced M3 affinity for CCL5.
M3-T272G was unable to inhibit 50% of CCL5 (Figure 3A) even
at the highest tested protein concentration (9x10−8 mol/l) used.
Thus, only the IC25 values of M3-T272G and wtM3 could be
compared, showing a significant reduction in M3-T272G affinity
for CCL5 (IC25 of 30.2 vs. 7.1 nmol/l for wtM3).
Similarly, the inhibition of CXCL8 by all M3’s, including
wtM3, was lower than that of CCL5, which never reached 50%
(Figure 4B). This fact is consistent with the previous finding
that M3 displays the lowest affinity for the CXC chemokine
subfamily members (Parry et al., 2000; van Berkel et al., 2000;
Matúšková et al., 2015). Comparing the IC25 values measured in
this study allows us to evaluate the affinities of all M3 proteins
for both chemokines (Figure 4). Both mutations reduced the
affinity of M3 for CXCL8: while E70A showed only a modest
reduction of 1.2× (IC25 of 11.5 vs. 8.7 nmol/l for wtM3), T272G
strongly diminished CXCL8 binding (IC25 of 42.5 vs. 8.7 nmol/l
for wtM3). To summarize an important result of this study is
the discovery that E70 is involved in the interactions of both
chemokines, but not substantially, and that the E70A mutation
enhanced M3’s affinity for CCL5. Further, T272 plays a critical
role in both CCL5 and CXCL8 binding and is important for M3
stability, while the T272Gmutation causes a significant reduction
in binding to both chemokines.
From the structural point of view, E70 is a surface-accessible
residue which is sterically close to the chemokine binding site,
though it is not part of the interface. Its substitution for an alanine
reduces the negative charge on the surrounding area of the NTD
(Figure 6B), but only moderately affects binding of CCL5 and
CXCL8 (Figure 4). Taken together, we propose that the effect of
this mutation on the affinities of CCL5 and CXCL8 very likely
does not arise from changes to the M3–chemokine interfaces or
from larger changes to the M3 structure, but from changes in the
way the two proteins approach and orient each other before full
binding actually occurs. Depending on the particular details of
the electrostatic surface of the interacting chemokine, therefore,
the E70 negative charge might help position the chemokine
correctly or slow its correct orientation. Both effects may be
present in the current situation. Although CXCL8 does make
the most charge-charge interactions in its binding to M3, it
actually has a lower overall surface charge than CCL5 (+3
e vs. +5 e). Moreover, in CXCL8 this charge is spread over
three different areas of the chemokine, while most of CCL5’s
charge is concentrated in a single location (in and around the
cleft between the C-terminal α-helix and the central β-sheet; cf.
Figure 5A vs. Figure 5C). This suggests that for CXCL8 binding,
the negative charge on E70 may help to position the chemokine
correctly for binding while its absence somewhat slows correct
positioning. For CCL5, on the other hand, it may be that E70
slows correct positioning while its absence makes it easier for the
positively charged cleft of the chemokine to associate with the
negatively-charged NTD, leading to the increase in affinity that
we see.
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By way of contrast, both chemokines bind substantially less
well to the M3-T272G mutant (Figure 4), and in both cases the
cause is very likely to be the same. Since T272 is both distant
from the binding site and buried, the T272G mutant is likely
to exert its effect indirectly. As this mutant has a lower stability
than wtM3, we speculate that it might cause some instability
in the CTD. Instability in the CTD would be expected to lead
to conformational changes to the CTD binding area, thereby
weakening the binding of both chemokines equally. In this case,
the slightly greater weakening of the CXCL8 interaction might
arise from the slightly greater interaction area the CTD makes
with this chemokine.
In conclusion, this study provides new insights into the
structural basis for M3–chemokine recognition and modulation
of M3-chemokine binding. Although not directly part of theM3–
chemokine interface, residues E70 and T272 in vitro modulate
the binding of both human CCL5 and CXCL8 chemokines.
The analysis of in silico modeled wtM3–CCL5 and wtM3–
CXCL8 complexes suggests a different way by which E70 and
T272 might affect chemokine binding: E70 via negative surface
charge reduction and T272 by structural change, resulting
in a substantial decrease in chemokine binding as well as a
diminishing of M3 stability. The results of this study indirectly
indicate that the E70A and T272G mutations might also affect
the signaling cascade in vivo, however, more experimental work
has to be performed to verify this consideration. They show
that mutations in M3 modulate (enhance or suppress) the
affinity of M3 for a specific chemokine in vitro. Our results
help better understand the broad specificity of M3 which makes
this protein an attractive potential therapeutic in situations
where dysregulated immune processes are accompanied by an
overabundance of chemokines.
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Figure S1 | Hydrophobicity/hydrophilicity profile in the vicinity of the mutation
sites. The mutation of M3 residues E70 to A70 and T272 to G272 resulted in
changes to the predicted hydrophobicity (A) and hydrophilicity (B) of the protein in
the area surrounding the mutations. A reduction in hydrophilicity was associated
with the E70 mutation (indicated by blue).
Figure S2 | SDS-PAGE (12.5%) analysis of the expression in E. coli Rosetta-gami
2 (DE3) cells and purification by IMAC of wtM3 and its mutants. (A) wtM3; (B)
M3-E70A; (C) M3-T272G. E indicates fractions eluted from the affinity column, the
arrow indicates wtM3 size (44 kDa).
Figure S3 | Superposition of the Cα traces of the CCL5 (blue), CCL2 (green),
CXCL8 (red) and XCL1 (orange chemokines). The greatest differences are seen in
the N-terminus and in the loop containing residues 30–36 (CCL5 numbering).
Details of the superposition are given in Table 1. Cysteines forming disulfide
bonds are indicated as balls and sticks and numbered; Sγ atoms are colored in
yellow, Cα and Cβ are colored according to the chemokine.
Table S1 | Forward and reverse primers used to prepare the M3 mutant
constructs.
Table S2 | Predicted properties of each M3 protein.
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